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EGFR = epidermal growth factor receptor; ER = estrogen receptor; GPCR = G-protein-coupled receptor; mER = membrane-bound estrogen
receptor.
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Abstract
Estrogen affects multiple aspects of human physiology, including
the normal growth and development of female reproductive
tissues, bone integrity, cardiovascular and central nervous system
functions, and plays a central role in normal mammary development
and breast pathogenesis. It modulates diverse cell signaling
pathways, some of which appear to be independent of the known
estrogen receptors (ERs). Although many of estrogen’s actions
can be explained by the nuclear ERs (ER-α and ER-β) functioning
as ligand-activated RNA transcription factors, there are numerous
rapid biochemical and physiological responses that cannot be
explained by the classical genomic effects of estrogen signaling. It
has long been postulated that the rapid effects of estrogen are due
to a membrane-bound ER, and two recent reports suggest that it is
in fact a G-protein-coupled receptor named ‘GPR30’.
In 1977 Pietras and Szego [1] showed that plasma mem-
branes prepared from endometrial and liver cells contain a
high-affinity estrogen-binding site, but this work was largely
ignored by breast cancer researchers and dismissed as a
result of experimental artifact due to contamination of the
membrane preparations with estrogen receptor (ER)-α.
Recent studies examining the identity of the membrane-bound
estrogen receptor (mER) have diverged into two schools of
thought, the first being that the mER is in fact the classical
nuclear ER-α (and ER-β) relocated to the plasma membrane
[2,3]; the second proposes that an orphan G-protein-coupled
receptor (GPCR) protein ‘GPR30’ is the mER [4,5].
In the ‘classic ER at the cell surface camp’, Levin and
colleagues (for review, see Evinger and Levin [3]) suggested
that the rapid effects of estrogen are mediated by a sub-
population of the nuclear ER-α and ER-β proteins, shuttled to
the plasma membrane by the scaffold protein caveolin-1, and
complexed with multiple signaling molecules, which then
functions as an atypical GPCR. Although their data are
intriguing and suggest that classical ERs may play a role in
cellular signaling outside the nucleus, this model is hard to
reconcile with other findings, such as the rapid effects of
estrogen on mouse hippocampal neurons from ER-knockout
mice.
There is a growing body of evidence suggesting that mER is
distinct from ER-α and ER-β, culminating in two recent
papers showing that an orphan GPCR, expression of which
tends to correlate with that of ER-α, binds directly to and can
be activated by estrogen [4,5]. This receptor, called GPR30,
may be involved in eliciting some of the effects of
17β-estradiol that were previously attributed to interactions
with ER-α and ER-β. The GPCRs as a group have perhaps
not been given the attention they deserve by many breast
cancer researchers because they are mostly viewed as
regulators of various ion channels and not directly involved in
cellular growth or differentiation. However, recent studies
have shown that GPCRs can influence cellular proliferation
and do so by transactivating growth factor receptors
including epidermal growth factor receptor (EGFR), platelet-
derived growth factor receptor, and insulin-like growth factor-1
receptor. This highlights the important role that this class of
receptor probably plays, both in normal mammary biology and
in the etiology and progression of breast cancer. Interestingly,
the estrogen-induced transactivation of EGFR that Levin’s
group attributes to the classical ER-α at the plasma membrane
[2] has also been shown to be mediated by GPR30 [6].
Crosstalk between GPR30 and EGFR is due to the rapid
proteolytic release of heparin-bound epidermal growth factor
by matrix metalloproteases, which allows the ligand to bind to
and activate EGFR.
Originally identified in a screen for neurotransmitter receptors
in a Burkitt’s lymphoma cell line, GPR30 was independently
cloned in 1997 by Weigel and colleagues [7], who were
conducting a differential screen of an MCF-7 cDNA library in
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an attempt to identify genes overexpressed in ER-positive
versus ER-negative breast cancers. They mapped GPR30 to
chromosome 7p22; its 2604 base pair transcript contains a
1126 open reading frame that encodes a 375 amino acid
protein, expression of which correlates with ER-α in breast
cancer cell lines and primary breast carcinomas. GPR30 has
significant sequence homology to the angiotensin II 1A,
interleukin 8A, and chemokine type 1 receptors, suggesting
that the protein might be the receptor for a peptide or
glycoprotein, although no such ligand has been found.
Others have shown that GPR30 is expressed in estrogen-
responsive tissues including breast, heart, leukocytes, brain,
and vascular endothelium (for review, see Filardo [8]).
The involvement of GPR30 in estrogen signaling was first
demonstrated by Filardo and coworkers [6] in 2000, when
they showed that estrogen-induced Erk-1/2 activation was
independent of known estrogen receptors. Although others
have demonstrated that this occurs in MCF-7 cells, Filardo
and colleagues showed that it also occurs in ER-α/β-
negative, GPR30-positive SKBR3 cells. Furthermore MDA-
MB-231 cells, which are GPR30-negative due to a genomic
deletion, are converted to an estrogen-responsive phenotype
by transfection with GPR30. Interestingly, they also showed
that the pure antiestrogen ICI 182,780 functions as an
agonist toward GPR30.
Although GPR30 was shown to be involved in the rapid
nongenomic effects of estrogen, it was not known whether
estrogen interacted directly with the GPCR or indirectly
through an unknown mER. Two nearly simultaneous reports
finally put this to rest, demonstrating that estrogen binds
directly to GPR30, making this protein a strong candidate for
the mER [4,5]. Thomas and coworkers [5] found that
estrogen binds to GPR30 with a Kd of 2.7 nmol/l, and that it
is a displaceable receptor with a single saturable binding site.
This work was conducted using the SKBR-3 cell line and an
ER-α/ER-β/GPR30-negative embryonic kidney cell line,
which only acquires estrogen-binding activity after trans-
fection with a GPR30 expression construct. In addition, they
demonstrated that tamoxifen and ICI 182,780 bind to GPR30
and appear to mimic the effects of estrogen. The effects of
ICI 182,780 are interesting, given the fact that this
compound has always been considered a pure antiestrogen.
These recent discoveries, coupled with the known actions of
GPR30 and its apparent coexpression in ER-α-positive
breast cancers and estrogen-responsive tissue, make it an
excellent candidate for being the true mER.
The work by Thomas and coworkers was confirmed by
Revankar and colleagues [4], who showed that GPR30 binds
to estrogen and fluorescent estrogen derivatives, and that
this binding results in increased intracellular calcium and
phosphatidylinositol 3,4,5-triphosphate. Although these two
groups concur on the estrogen-binding characteristics of
GPR30, they disagree on its cellular localization. Thomas and
coworkers believe that GPR30 is located at the plasma
membrane, whereas the findings reported by Revanker and
colleagues [4], using a fluorescently linked GPR30, suggest
that it is located within the endoplasmic reticulum – a
conclusion apparently supported by additional studies using
a fluorescent marker to locate native GRP30 in several cell
lines. These data, which seem to contradict previous studies
of GPR30 subcellular distribution, may have added to some
of the confusion as to whether GPR30 is indeed the true
mER. Nevertheless, the identification, characterization, and
demonstration of the estrogen-binding characteristics of
GPR30 certainly merit serious consideration by breast
cancer researchers that it is a potentially important player in
estrogen signaling in the breast.
In conclusion, the literature is replete with studies demonstrating
that estrogen can produce a panoply of effects in cells, such as
alterations in calcium flux, activation of adenyl cyclase, mitogen-
activated protein kinase, among others, that in other systems are
seen as a result of the activation of GPRCs. The assumption
heretofore has been that these effects were most likely
mediated by the canonical ERs (ER-α and ER-β); however,
given that in most cases the culture systems used also express
GPR30, this assumption needs to be tested. It may be that a
better understanding of the role played by GPR30 in global
estrogen signaling will provide insight into some of the most
challenging and longstanding questions in breast cancer
research, such as how estrogen signaling is involved in
mammary carcinogenesis, the relationship between estrogen
responsive and refractory disease, and the mechanisms by
which previously hormone responsive tumors elude that control.
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